BioGnost
BioGnost is a Croatian medical-products company specializing in in-vitro diagnostic reagents, rapid tests, and laboratory products.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
BioGnost Ltd. is a Croatian medical-products and in-vitro diagnostics company headquartered in Zagreb. Founded in 1990 by Ivan Marchiotti, MD, and Mirjana Marchiotti-Ulip, MPharm, the company developed from a domestic laboratory-products manufacturer into a supplier serving Croatia, Southeastern Europe, and export markets. Its activities cover the manufacture and distribution of reagents and related products used in histopathology, cytology, hematology, microbiology, immunohematology, immunohistochemistry, and rapid diagnostic testing. The BioGnost brand became formally established in 1997, when the Croatian Ministry of Health granted the company authorization to manufacture in-vitro medical diagnostic products. That year also saw the beginning of blood-typing serum production and the registration of the BioGnost trademark with the Croatian Intellectual Property Office. The company subsequently expanded into rapid immunochromatographic tests, including products for pregnancy testing, detection of drug metabolites, and identification of infectious diseases. Its rapid-test portfolio helped establish the company as a recognizable supplier in the regional diagnostic market. Distribution became an important part of the business. BioGnost signed its first distribution agreements with foreign partners in 1998 and later created affiliated operations in Serbia and Bosnia and Herzegovina. A representative office in Belgrade opened in 2003, followed by BioGnost S in Belgrade in 2010 and BioGnost BH in Sarajevo in 2011. These structures supported the company's regional reach and provided a platform for serving neighboring markets. Quality management and regulatory capability have been recurring strategic priorities. BioGnost implemented ISO 9001 in 2003 and became the first company in Croatia reported to have implemented ISO 13485 in 2005. The latter standard is particularly relevant to medical-device and in-vitro diagnostic quality systems. The company also began marketing a portfolio of more than 240 registered brand-name products during the 2000s and developed OEM manufacturing relationships with foreign partners later in its history. Product development broadened during the 2010s. The company introduced a diabetes-related sales range in 2012, expanded its microscopy products with BioMount mounting media and immersion oils, and developed CryoFix Gel and special staining kits for histopathology. Participation in Croatian and European Union-supported innovation projects contributed to the development of staining systems and immunohistochemistry products, including LeukoGnost. BioGnost also invested in green and digital transition initiatives and in innovations intended to improve production and delivery activities. The company has pursued international visibility through recurring participation in Medica in Düsseldorf and Medlab Middle East in Dubai. Its first participation at Medica took place in 2013, while the company later exhibited repeatedly at both events to develop distributor relationships and expand exports. In 2020, BioGnost was described as the only Croatian exhibitor at Medlab Middle East. Its business also includes institutional and healthcare-related work, such as the 2019 completion of equipment for two wings of Sveti Duh Clinical Hospital in Zagreb. BioGnost remains an active, privately held Croatian diagnostics business with a positioning centered on laboratory quality, regional accessibility, product breadth, and export development. Publicly available reference material does not establish a current chief executive, ownership structure, revenue figure, or official corporate website.
History
BioGnost was established in Zagreb in 1990 by Ivan Marchiotti, MD, and Mirjana Marchiotti-Ulip, MPharm. The early business focused on medical and laboratory products, eventually developing manufacturing capabilities in in-vitro diagnostics and related laboratory categories. A major regulatory milestone arrived in 1997, when Croatia's Ministry of Health granted BioGnost a license to manufacture in-vitro medical diagnostic products. The company began producing blood-typing sera, registered the BioGnost brand as a trademark in Croatia, and expanded into rapid immunochromatographic tests for pregnancy, drug metabolites, and infectious diseases. In 1998, it signed its first foreign distribution agreements. During the early 2000s, rapid tests became an important part of the company's commercial activity. BioGnost distributed tests for drug-metabolite detection, including AbuGnost and DOA MultiGnost products. The company also strengthened its institutional systems: it implemented ISO 9001 in 2003, opened a representative office in Belgrade, and began marketing a portfolio exceeding 240 registered brand-name products. In 2005, it became the first Croatian company reported to have implemented ISO 13485. The company also introduced a workplace-protection system addressing the harmful influence of alcohol and illegal drugs. Public-health collaboration became visible in 2007, when BioGnost distributed HemoGnost tests through Croatia's National Colorectal Cancer Screening Program. Regional expansion followed through the establishment of BioGnost S in Belgrade in 2010 and BioGnost BH in Sarajevo in 2011. In 2012, headquarters moved from the Savica Šanci Center for Small Business to a commercial and manufacturing building on Međugorska Street in Zagreb. A diabetes-related product range was also launched. Internationalization accelerated in the 2010s. BioGnost first exhibited at Medica in Düsseldorf in 2013 and subsequently returned to the event. It also participated in Medlab Middle East in Dubai, using both exhibitions to meet distributors and expand foreign business. Manufacturing and product development broadened through BioMount covering media, immersion oils, CryoFix Gel, special histopathology staining kits, and immunohistochemistry products. The LeukoGnost product was identified as an early result of the company's immunohistochemistry development work. BioGnost also began OEM manufacturing for foreign partners. The company participated in Croatian and EU-supported projects involving product certification, production innovation, delivery processes, immunohistochemistry, and later green and digital transition. In 2019, it completed equipment work for the northwest and southeast wings of Sveti Duh Clinical Hospital in Zagreb. In 2020, it continued EU-funded initiatives while maintaining international exhibition activity. Work on these projects continued in 2022, and another EU co-financed production and delivery project was completed in 2023. BioGnost's documented history shows an evolution from a Croatian diagnostic-products manufacturer into a broader laboratory and medical-products company with regional affiliates, export ambitions, and OEM capabilities. The available reference material does not identify current management beyond the founders, disclose ownership or financial performance, or provide a confirmed official website.
- 2023
EU co-financed innovation project completed
[1]BioGnost completed another EU co-financed project aimed at improving production and delivery activities and presented products at Medlab Middle East.
- 2021
Green and digital transition investments
[1]EU-supported work funded investments in the company's green and digital transition.
- 2020
New EU-funded projects begin
[1]The company began two EU-funded projects focused on production and delivery innovation and immunohistochemistry products.
- 2019
Clinical-hospital equipment project completed
[1]BioGnost completed equipment work for two wings of Sveti Duh Clinical Hospital in Zagreb.
- 2017
EU funding for certification
[1]BioGnost received EU funding connected with product certification.
- 2016
Histopathology and immunohistochemistry development
[1]Projects produced ten special histopathology staining kits and supported development of immunohistochemistry products, including LeukoGnost. OEM manufacturing for foreign partners also began.
- 2013
First Medica exhibition
[1]BioGnost participated for the first time in Medica in Düsseldorf, Germany.
- 2012
Headquarters relocation and diabetes range
[1]The company moved to a new commercial and manufacturing building in Zagreb and launched a diabetes-related sales range.
- 2011
Bosnian sister company established
[1]BioGnost BH was founded in Sarajevo, Bosnia and Herzegovina.
- 2010
Serbian sister company established
[1]BioGnost S was founded in Belgrade, Serbia.
Products and positioning
A Croatian and Southeastern European medical-diagnostics supplier combining in-vitro diagnostic manufacturing, laboratory reagents, rapid tests, regional distribution, and OEM production. Its positioning emphasizes regulated quality systems, broad laboratory coverage, and export-oriented partnerships.
Occult-blood and colorectal screening tests · 2007
HemoGnost
HemoGnost tests were distributed through Croatia's National Colorectal Cancer Screening Program beginning in 2007. The product line illustrates BioGnost's role in supplying rapid or accessible diagnostic tools for public-health screening.
Drug-metabolite rapid tests
AbuGnost
AbuGnost is identified in reference material as part of BioGnost's rapid testing activity for detecting drug metabolites. It contributed to the company's early expansion of home-use and point-of-care diagnostic products.
Multi-analyte drug-screening tests
DOA MultiGnost
DOA MultiGnost is a home-use rapid test associated with BioGnost's drug-metabolite testing portfolio. Reference material links its growth to increasing demand and public awareness of the company's rapid-test products.
Histopathology mounting media · 2014
BioMount
BioMount comprises covering media used in microscopy and histopathology. In 2014, BioGnost optimized production of ten BioMount products, indicating a substantial product family within its laboratory-materials portfolio.
Histopathology laboratory product · 2015
CryoFix Gel
CryoFix Gel was highlighted among the new products added to BioGnost's portfolio in 2015. The available reference identifies it as a histopathology-related development but does not provide detailed technical specifications.
Immunohistochemistry product · 2016
LeukoGnost
LeukoGnost was identified as BioGnost's first product arising from an immunohistochemistry development project. It reflects the company's move beyond conventional laboratory reagents into more specialized tissue-analysis applications.
Immunohematology reagent · 1997
Blood-typing sera
BioGnost began manufacturing blood-typing sera after receiving Croatian authorization for in-vitro diagnostic production in 1997. These products formed part of the company's early regulated diagnostic-manufacturing base.
Marketing campaigns
- 2017Medlab Middle East expansion
United Arab Emirates · Middle East · International
BioGnost exhibited at Medlab Middle East in Dubai as part of its export-development and distributor-building activity.
Outcome. The company continued participating and used the event to establish additional international contacts.
- 2013Medica international exhibition program
Germany · International
BioGnost began exhibiting at Medica in Düsseldorf to present histopathology, immunohematology, and rapid diagnostic products to international buyers and distributors.
Outcome. The company reported increased foreign contacts and new business partnerships.
- 2007National Colorectal Cancer Screening Program support
Croatia
BioGnost distributed HemoGnost tests as part of Croatia's national colorectal cancer screening initiative.
Outcome. The cooperation continued beyond the initial launch, according to the reference material.
Brand decisions
2020
Invest in production, delivery, and immunohistochemistry innovationStrategyBackground
BioGnost pursued publicly supported projects to improve its manufacturing activities and develop specialized diagnostic products.
Action taken
It began two EU-funded projects focused on production and delivery innovation and immunohistochemistry.
Aftermath
The projects were followed by green and digital transition investments and further work completed in 2023.
2013
Increase international export developmentStrategyBackground
BioGnost wanted to strengthen foreign distribution and broaden its international customer base.
Action taken
The company began exhibiting at Medica and later expanded its presence at international laboratory exhibitions.
Aftermath
The company reported more foreign contacts, distributor relationships, and business partnerships.
1997
Enter licensed in-vitro diagnostic manufacturingStrategyBackground
BioGnost sought to establish a regulated manufacturing base in medical diagnostics.
Action taken
The company obtained Croatian authorization, started producing blood-typing sera, and registered the BioGnost brand.
Aftermath
The authorization enabled expansion into rapid tests and other diagnostic product categories.
Recent events
- 2021
BioGnost reports continued EU-backed production and digital-transition work[1]
Other
EU-supported projects included investments intended to advance the company's green and digital transition.
- 2017
BioGnost participates in EU-supported innovation and certification projects[1]
Other
The company received European Union funding related to product certification and continued developing diagnostic products through publicly supported innovation projects.
- 2013
BioGnost increases international exhibition activity[1]
Other
The company first exhibited at Medica in Düsseldorf and continued using international trade fairs to develop export contacts and partnerships.
- 2011
BioGnost expands regional operations with Serbian and Bosnian affiliates[1]
Other
After establishing BioGnost S in Belgrade in 2010, the company founded BioGnost BH in Sarajevo in 2011.
- 2007
BioGnost launches HemoGnost distribution for Croatia's colorectal cancer screening program[1]
Other
BioGnost began distributing HemoGnost tests in connection with Croatia's National Colorectal Cancer Screening Program.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/biognost · Editorial policy · How profiles are compiled